Pepex Biomedical
Pepex® Biomedical develops advanced biosensors and cloud-connected glucose meters, enhancing diabetes care and diagnostics.
Founded
2001Pepex® Biomedical develops advanced biosensors and cloud-connected glucose meters, enhancing diabetes care and diagnostics.
Pepex® Biomedical, founded with the mission to revolutionize diabetes care, is a medical device and healthcare technology company. It specializes in developing advanced enzymatic-based biosensors and cloud-connected glucose meters. With a vision to create the industry's first big data platform dedicated to diabetes, Pepex aims to enhance patient care and diagnostics through innovative sensor designs that measure metabolic analytes at the cellular level. The company holds 246 patents worldwide, underscoring its commitment to pioneering technology in the healthcare sector.
Notable figures affiliated with Pepex Biomedical include its officers and directors, who bring extensive experience in medical technology and business leadership. The company has achieved significant milestones, including the development of a wirelessly enabled diagnostic blood glucose measuring system that connects to the cloud. This innovation positions Pepex as a disruptive force in the medical device industry. Through its advanced biosensor technology, Pepex Biomedical is making a substantial impact on diabetes management and patient outcomes globally.
Companies similar to Pepex Biomedical include BioSens8, Biorasis, Perle Bioscience and Integrated Medical Sensors.
Pepex Biomedical was founded in 2001.
Pepex Biomedical's headquarters is located in St. Louis, MO, US.
Pepex Biomedical's most recent funding round was for $15M (USD) in July 2015.
As of Jul 2, 2015, Pepex Biomedical has disclosed funding of $22.3M (USD). Undisclosed round amounts are excluded.
Pepex Biomedical has 8 employees as of Feb 4, 2024.
